We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Ingestible Micro-Robot Wirelessly Navigates Stomach for Remote Diagnosis of GI Tract

By HospiMedica International staff writers
Posted on 15 Jul 2024

Four out of five upper endoscopies typically result in negative outcomes, indicating no medical issues within the patient's stomach that require treatment. More...

Now, an ingestible micro-robot designed to wirelessly navigate the human stomach offers a breakthrough in gastrointestinal (GI) care.

Endiatx (Hayward, CA, USA) has launched PillBot, a revolutionary micro-robot designed to navigate the human stomach, offering a non-invasive, cost-effective alternative for GI diagnostics and treatment. Roughly the size of a vitamin pill, PillBot provides live video feedback as it moves through the water-filled stomach. After a patient ingests water and swallows the PillBot, a physician can remotely control the device using an internet-connected game controller to conduct a comprehensive scan of the stomach. This innovative approach reduces the need for more invasive procedures, lowers costs, and improves accessibility of GI diagnostic and treatment services. PillBot aims to spare many patients the discomfort associated with sedation and hospital visits, while also offering insurers a more economical option. Additionally, this device could help optimize hospital resources by identifying cases that require further investigation following an initial PillBot examination.

Endiatx plans to seek FDA clearance for PillBot following the completion of its clinical trials later this year, with a projected commercial launch in the U.S. by early 2026 and subsequent expansion into international markets, especially in developing countries where GI medical resources are scarce. The ongoing clinical trials have yielded promising results, demonstrating PillBot’s effectiveness and safety in practical applications. Going forward, Endiatx is exploring the integration of artificial intelligence (AI) technology into PillBot to enhance its diagnostic capabilities, potentially enabling routine screenings and acute care diagnostics. Such advancements could improve the early detection of conditions like stomach cancer, which is responsible for nearly 800,000 deaths worldwide annually. An AI-enhanced PillBot would autonomously navigate the stomach, analyze data, and deliver precise diagnostics, thus streamlining and improving the efficiency of GI care.

Related Links:
Endiatx


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Hospital Stretcher
Millennium 5
New
Infusion System
SIGMA Spectrum
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.